Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Hot Products

Closely following Pralsetinib, the second RET inhibitor in China was applied for production

PharmaSources/YiDecember 02, 2021

Tag: Selpercatinib Capsule , NSCLC , RET inhibitors